Why Is CRISPR THERAPEUTICS (CRSP) Stock Down Today?

Crispr Therapeutics (CRSP) shares fell 9.77% to $45.15, a move driven by a recent 40% drop in short interest that signals deteriorating bearish sentiment. The decline follows a period of mixed analyst commentary and significant insider selling activity.

What Happened

The stock’s movement coincides with a sharp reduction in short interest, which some market observers interpret as a sign that bearish positioning is weakening. Piper Sandler reiterated its overweight rating on the stock, while other analysts have issued conflicting views, including a strong sell recommendation citing overvaluation despite Casgevy sales growth. The company announced that senior management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. Additionally, Crispr Therapeutics presented Phase 1b data for CTX310 at the American Heart Association Scientific Sessions 2026, showing a mean reduction from baseline of 65% in ANGPTL3 and 63% in triglycerides for patients with severe hypertriglyceridemia.

What The Data Shows

Fundamentals indicate the company remains unprofitable with a trailing twelve-month EPS of -4.75 and revenue down 34.3%. The stock carries a beta of 1.90 and a market cap of $4.9 billion. Over the last eight sessions, the stock has moved down 12.2% from $51.42 to $45.15. The 52-week range is $44.12 to $63.45, with the current price near the lower end of that band. Recent SEC Form 4 filings show seven sells totaling $4.9 million in the last 90 days, with no buys recorded. CEO Samarth Kulkarni sold shares on October 19 and October 14, 2026, while General Counsel James R. Kasinger sold on October 14, 2026.

What To Watch

Investors will monitor the upcoming fireside chat at the 2026 Jefferies Global Healthcare Conference for further guidance. The stock’s proximity to its 52-week low and the recent shift in short interest levels remain key metrics to observe as the company continues to present clinical data for its gene editing therapies.